This picture taken on May 23, 2020 shows a laboratory technician holding a dose of a COVID-19 novel coronavirus vaccine candidate ready for trial on monkeys at the National Primate Research Center of Thailand at Chulalongkorn University in Saraburi. (Photo by MLADEN ANTONOV/AFP via Getty Images)
OAN Newsroom
UPDATED 7:05 PM PT – Wednesday, November 18, 2020
Pfizer officials have stated additional analysis from its experimental coronavirus vaccine suggested it’s more than 95 percent effective in preventing COVID-19.
On Wednesday, Pfizer and BioNTech released the updated data after initially estimating last week their vaccine was more than 90 percent effective.
BREAKING: We are proud to announce, along with @BioNTech_Group, that the Phase 3 study of our #COVID19 vaccine candidate has met all primary efficacy endpoints.
— Pfizer Inc. (@pfizer) November 18, 2020
The drugmakers stated its effectiveness was consistent across all ages, races and ethnicities with no serious side effects. Additionally, BioNTech’s CEO plans to submit an emergency use authorization to the FDA within days.
MORE NEWS: ICE Arrests 180 Immigrants In ‘Operation Broken Promise’
Be the first to comment